![](https://endpts.com/wp-content/uploads/2024/06/Merck-Daiichi-Sankyo-tile1.jpg)
FDA rejects Daiichi Sankyo's HER3 ADC, a blow to quick approval plans for Merck partnership
The FDA has given a thumbs-down to Daiichi Sankyo’s HER3 antibody-drug conjugate patritumab deruxtecan.
The Wednesday rejection deals a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.